Indivior Pharmaceuticals, Inc. (INDV)
35.08
+0.52
(+1.50%)
USD |
NASDAQ |
Sep 02, 10:41
Indivior Pharmaceuticals Research and Development Expense (Annual) : 80.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 80.00M |
| December 31, 2024 | 107.00M |
| December 31, 2023 | 116.00M |
| December 31, 2022 | 72.00M |
| December 31, 2021 | 52.00M |
| December 31, 2020 | 40.00M |
| December 31, 2019 | 53.00M |
| December 31, 2018 | 67.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 89.00M |
| December 31, 2016 | 119.00M |
| December 31, 2015 | 148.00M |
| December 31, 2014 | 115.00M |
| December 31, 2013 | 76.00M |
| December 31, 2012 | 41.00M |
| December 31, 2011 | 35.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Supernus Pharmaceuticals, Inc. | 104.13M |
| Liquidia Corp. | 38.45M |
| Corcept Therapeutics, Inc. | 254.91M |
| Prestige Consumer Healthcare, Inc. | -- |
| Harrow, Inc. | 12.85M |